The effects that granulocyte-monocyte colony-stimulating factor (GM-CSF) has on HIV-1 replication in monocyte-derived macrophage are controversial. We noted that groups reporting that GM-CSF inhibits HIV-1 replication performed their experiments at relatively high cell densities. To address this issue, we performed experiments at different macrophage densities. In cultures seeded at low cell densities, we find that adding GM-CSF during the first week of culture (ie, before infection, during maturation) increased viral replication compared with that in untreated controls in 10 of 11 donors with quantifiable HIV-1 replication. (No effects were observed if GM-CSF was added after the first week of culture.) In cultures seeded at the higher cell densities representative of those in some previous studies, adding GM-CSF during the first week reduced subsequent viral replication in 8 of 12 donors. In all cases in which GM-CSF reduced viral replication, however, the pH in the wells containing GM-CSF-treated cells dropped dramatically. Macrophages in these acidified cultures had numerous dark granules, suggesting that they were under stress. We conclude, contrary to previous reports, that GM-CSF usually enhances viral replication when cells are grown at low densities in which excessive medium acidification can be prevented. Our results illustrate the dramatic effects that in vitro tissue culture conditions can have when studying the effect of cytokines on HIV-1 replication.

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAI.0b013e318030f5c5DOI Listing

Publication Analysis

Top Keywords

hiv-1 replication
20
viral replication
16
cell densities
12
gm-csf week
12
replication
9
granulocyte-monocyte colony-stimulating
8
colony-stimulating factor
8
replication monocyte-derived
8
performed experiments
8
cultures seeded
8

Similar Publications

Anatomical, subset, and HIV-dependent expression of viral sensors and restriction factors.

Cell Rep

January 2025

Gladstone Institutes, San Francisco, CA, USA; Department of Urology, UCSF, San Francisco, CA, USA. Electronic address:

We developed viral sensor and restriction factor-cytometry by time of flight (VISOR-CyTOF), which profiles 19 viral sensors and restriction factors (VISORs) simultaneously in single cells, and applied it to 41 postmortem tissues from people with HIV. Mucosal myeloid cells are well equipped with SAMHD1 and sensors of viral capsid and DNA while CD4 T cells are not. In lymph node CD4 Tfh, VISOR expression patterns reflect those favoring integration but blocking HIV gene expression, thus favoring viral latency.

View Article and Find Full Text PDF

The integration of nanotechnology into antiretroviral drug delivery systems presents a promising avenue to address challenges posed by long-term antiretroviral therapies (ARTs), including poor bioavailability, drug-induced toxicity, and resistance. These limitations impact the therapeutic effectiveness and quality of life for individuals living with HIV. Nanodrug delivery systems, particularly nanoemulsions, have demonstrated potential in improving drug solubility, enhancing bioavailability, and minimizing systemic toxicity.

View Article and Find Full Text PDF

Major role of dolutegravir in the emergence of the S147G integrase resistance mutation.

J Antimicrob Chemother

December 2024

Department of Virology, Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, 83 Boulevard de l'Hôpital 39, F-75013 Paris, France.

Background: The S147G mutation is associated with high-level resistance to the integrase strand transfer inhibitor (INSTI) elvitegravir. In several poorly documented cases, it was also selected in patients on dolutegravir. Given the widespread use of dolutegravir, further studies of S147G are required.

View Article and Find Full Text PDF

Antiretroviral therapy (ART) improves the quality of life for those living with the human immunodeficiency virus type one (HIV-1). However, poor compliance reduces ART effectiveness and leads to immune compromise, viral mutations, and disease co-morbidities. Here we develop a drug formulation in which a lipid-based nanoparticle (LBNP) carrying rilpivirine (RPV) is decorated with the C-C chemokine receptor type 5 (CCR5) targeting peptide.

View Article and Find Full Text PDF

The only cure of HIV has been achieved in a small number of people who received a hematopoietic stem cell transplant (HSCT) comprising allogeneic cells carrying a rare, naturally occurring, homozygous deletion in the CCR5 gene. The rarity of the mutation and the significant morbidity and mortality of such allogeneic transplants precludes widespread adoption of this HIV cure. Here, we show the application of CRISPR/Cas9 to achieve >90% CCR5 editing in human, mobilized hematopoietic stem progenitor cells (HSPC), resulting in a transplant that undergoes normal hematopoiesis, produces CCR5 null T cells, and renders xenograft mice refractory to HIV infection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!